Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Follow-Ons, Private Placements Remain Active
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
